Bio-Techne To Present At The Stifel 2020 Virtual Healthcare Conference

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) will have its CEO, Chuck Kummeth, present at the Stifel 2020 Virtual Healthcare Conference on November 16, 2020, at 1:20 p.m. EST. Interested parties can access a live webcast through the Investor Relations website. Bio-Techne specializes in producing high-quality proteins and diagnostic tools used in biomedical research and clinical laboratories. In fiscal 2020, the company reported approximately $739 million in net sales and employs over 2,300 people globally.

MINNEAPOLIS, Nov. 4, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 1:20 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx^® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $739 million in net sales in fiscal 2020 and has over 2,300 employees worldwide.

Contact:	David Clair, Senior Director, Investor Relations & Corporate Development
	david.clair@bio-techne.com
	612-656-4416

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-stifel-2020-virtual-healthcare-conference-301166019.html

SOURCE Bio-Techne Corporation

FAQ

When is Bio-Techne's presentation at the Stifel 2020 Virtual Healthcare Conference?

Bio-Techne's presentation will be on November 16, 2020, at 1:20 p.m. EST.

What is Bio-Techne Corporation known for?

Bio-Techne is known for developing high-quality purified proteins and diagnostic products used in biomedical research.

How much in net sales did Bio-Techne generate in fiscal 2020?

Bio-Techne generated approximately $739 million in net sales in fiscal 2020.

What products does Bio-Techne offer?

Bio-Techne offers products including cytokines, antibodies, immunoassays, genomic tools, and diagnostic products.

Where can I watch the live webcast of Bio-Techne's conference presentation?

The live webcast can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website.